olomorasib + durvalumab

Olomorasib + durvalumab is an investigational combination therapy for unresectable KRAS G12C-mutant non-small cell lung cancer (NSCLC). **Olomorasib** is a highly selective, oral, covalent small molecule inhibitor of the KRAS G12C mutant protein, developed for targeting oncogenic signaling in cancer cells[5]. **Durvalumab** is a monoclonal antibody targeting PD-L1, blocking its interaction with PD-1 and CD80, thereby enhancing anti-tumor immune responses. The combination is being studied as part of a phase 3 clinical trial (SUNRAY-02, NCT06890598), particularly in NSCLC, with a regimen of olomorasib and durvalumab given for up to 1 year, followed by olomorasib monotherapy. This approach aims to overcome resistance mechanisms and augment clinical efficacy by pairing targeted therapy with immunotherapy[4][7]. The developer and manufacturer for olomorasib is Eli Lilly, while durvalumab is developed and manufactured by AstraZeneca.

Other names

olomorasib + durvalumab